source
- AstraZeneca reports Phase 3 trial shows Imfinzi-Padcev combo improves survival in bladder cancerAstraZeneca announced that its Phase 3 study of the immunotherapy Imfinzi combined with the antibody‑drug conjugate Padcev, developed with Pfizer and Astellas, extended overall survival for patient…
- BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphomaBeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma. The approval is based on…